Prime Radiant Partners‘ Prime Radiant Fund SLP SICAV-RAIF, a fund advised by the firm, has invested $50 million in Cellares, marking the fund’s first investment since the firm’s launch in 2025.
Cellares is developing an integrated development and manufacturing organization (IDMO) model designed to automate large-scale cell therapy manufacturing. The investment adds Prime Radiant to an existing investor base that includes funds managed by BlackRock, Eclipse, T. Rowe Price Investment Management, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, Gates Frontier, DC Global Ventures, Willett Advisors, DFJ Growth and ARK Invest.
Based in California, Cellares provides automated clinical and commercial manufacturing services for cell and gene therapies through its proprietary Cell Shuttle platform. Cellares is expanding its network of IDMO Smart Factories across the U.S., Europe and Japan to support pharmaceutical and biotechnology customers developing next-generation therapies.